22 December 2025
Watkin Jones plc (‘Watkin Jones’ or the ‘Group’) Development Partnership for 294-unit hotel in Wimbledon Watkin Jones, the UK’s leading developer and manager of…
LONDONMETRIC PROPERTY PLC LONDONMETRIC TRANSACTS ON £91 MILLION OF INVESTMENT ACTIVITY LondonMetric Property Plc (“LondonMetric”) announces that it has sold £64.4 million of retail assets…
GSK enters agreement with U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans GSK plc (LSE/NYSE: GSK)…
Enhertu granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer Tenth Breakthrough Therapy Designation for AstraZeneca and…
Update on LATIFY Phase III trial of ceralasertib plus Imfinzi in previously treated advanced non-small cell lung cancer The LATIFY Phase III trial of ceralasertib in…
18 December 2025
HARWORTH GROUP PLC (‘Harworth’ or the ‘Group’ or the ‘Company’) Harworth secures 267,000 sq ft of I&L Investment Portfolio lettings, delivering £2.5m of annualised…
17 December 2025
LONDON STOCK EXCHANGE ANNOUNCEMENT JPMORGAN INDIA GROWTH & INCOME PLC FINAL RESULTS FOR THE YEAR ENDED 30TH SEPTEMBER 2025 Legal Entity Identifier: 549300OHW8R1C2WBYK02 Information…
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma · Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients…